FI963103A0 - Ei-virusvektori - Google Patents

Ei-virusvektori

Info

Publication number
FI963103A0
FI963103A0 FI963103A FI963103A FI963103A0 FI 963103 A0 FI963103 A0 FI 963103A0 FI 963103 A FI963103 A FI 963103A FI 963103 A FI963103 A FI 963103A FI 963103 A0 FI963103 A0 FI 963103A0
Authority
FI
Finland
Prior art keywords
viral vector
cell
biotin
administration
human
Prior art date
Application number
FI963103A
Other languages
English (en)
Swedish (sv)
Other versions
FI963103A (fi
Inventor
Michael G Rosenblum
Nicholas J Donato
Original Assignee
Res Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Dev Foundation filed Critical Res Dev Foundation
Publication of FI963103A0 publication Critical patent/FI963103A0/fi
Publication of FI963103A publication Critical patent/FI963103A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI963103A 1994-02-07 1996-08-06 Ei-virusvektori FI963103A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19265594A 1994-02-07 1994-02-07
PCT/US1995/001161 WO1995021195A1 (en) 1994-02-07 1995-02-06 Non-viral vector

Publications (2)

Publication Number Publication Date
FI963103A0 true FI963103A0 (fi) 1996-08-06
FI963103A FI963103A (fi) 1996-10-01

Family

ID=22710534

Family Applications (1)

Application Number Title Priority Date Filing Date
FI963103A FI963103A (fi) 1994-02-07 1996-08-06 Ei-virusvektori

Country Status (16)

Country Link
US (1) US6214974B1 (fi)
EP (1) EP0743958B1 (fi)
JP (1) JP4015693B2 (fi)
KR (1) KR100376390B1 (fi)
CN (1) CN1200950C (fi)
AT (1) ATE245662T1 (fi)
AU (1) AU695564B2 (fi)
CA (1) CA2182616A1 (fi)
DE (1) DE69531342D1 (fi)
FI (1) FI963103A (fi)
IL (1) IL112372A (fi)
NO (1) NO319899B1 (fi)
NZ (1) NZ281763A (fi)
RU (1) RU2164943C2 (fi)
SA (1) SA95150519B1 (fi)
WO (1) WO1995021195A1 (fi)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ237688A (en) * 1990-04-19 1993-01-27 Res Dev Foundation Antibody-cytotoxic immunoconjugate-containing compositions and cancer treatment
WO1995022086A1 (en) * 1994-02-08 1995-08-17 Nippon Steel Corporation Liquid development type multi-color image formation apparatus
DE19605279A1 (de) * 1996-02-13 1997-08-14 Hoechst Ag Zielzellspezifische Vektoren für die Einschleusung von Genen in Zellen, Arzneimittel enthaltend derartige Vektoren und deren Verwendung
EP1098666B1 (en) * 1998-07-17 2013-01-16 The United States of America, represented by the Secretary, Department of Health and Human Services Water-soluble drugs and methods for their production
FR2793414B1 (fr) * 1999-05-10 2003-05-23 Centre Nat Rech Scient Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules
GB9930533D0 (en) * 1999-12-23 2000-02-16 Mitsubishi Tokyo Pharm Inc Nucleic acid delivery
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
US7265208B2 (en) * 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
EP1404707A4 (en) * 2001-05-29 2005-02-02 Univ Michigan SYSTEMS AND METHODS FOR PROTEIN ANALYSIS
WO2002102972A2 (en) * 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
ATE477280T1 (de) * 2001-06-28 2010-08-15 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
CN1555268B (zh) * 2001-07-17 2013-04-03 研究发展基金会 含促调亡蛋白质的治疗剂
AU2002323845A1 (en) * 2002-04-02 2003-10-13 "Asgl-Farmatsevticheskie Innovatsii", Zakrytoe Aktsionernoe Obschestvo Recombinant chimeric protein for the target delivery of dna to eukariotic target cells
CA2488858A1 (en) * 2002-06-12 2003-12-24 Research Development Foundation Immunotoxin as a therapeutic agent and uses thereof
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
JP2006512895A (ja) * 2002-06-28 2006-04-20 ドマンティス リミテッド リガンド
EP1578801A2 (en) * 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
WO2005074417A2 (en) * 2003-09-03 2005-08-18 Salk Institute For Biological Studies Multiple antigen detection assays and reagents
CN101104856B (zh) * 2003-11-18 2010-11-10 中国医学科学院基础医学研究所 一个系列的非病毒载体及包含其的药物组合物
US20060171919A1 (en) * 2005-02-01 2006-08-03 Research Development Foundation Targeted polypeptides
CA2632866A1 (en) * 2005-12-01 2007-06-07 Domantis Limited Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
EA200901301A1 (ru) * 2007-06-06 2010-06-30 Домантис Лимитед Полипептиды, вариабельные домены антител и антагонисты
TWI689314B (zh) 2010-11-30 2020-04-01 建南德克公司 低親和力血腦障壁受體抗體及其用途
US9623117B2 (en) * 2011-04-04 2017-04-18 Wisconsin Alumni Research Foundation Method for selective targeting and entry of bacterial toxins to cells
KR20140146993A (ko) 2011-05-11 2014-12-29 칠드런'즈 메디컬 센터 코포레이션 다항원 제시 면역성 조성물, 및 그 방법 및 용도
US11576958B2 (en) 2013-02-07 2023-02-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
UY36519A (es) * 2015-01-16 2016-08-31 Hope City Anticuerpos de penetración celular
AU2018243910A1 (en) 2017-03-28 2019-11-14 The Children's Medical Center Corporation A multiple antigen presenting system (MAPS)-based staphylococcus aureus vaccine, immunogenic composition, and uses thereof
CN111065417B (zh) 2017-06-23 2024-04-19 美商艾芬尼维克斯公司 免疫原性组合物
JP2021535921A (ja) 2018-09-12 2021-12-23 アフィニバックス、インコーポレイテッド 多価肺炎球菌ワクチン
CN116848146A (zh) 2020-09-03 2023-10-03 I·S·Y·陈 可溶性碱性磷酸酶构建体和包含编码可溶性碱性磷酸酶构建体的多核苷酸的表达载体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4545985A (en) * 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
US5525338A (en) * 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
US4863713A (en) * 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
US5026785A (en) * 1989-05-12 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Avidin and streptavidin modified water-soluble polymers such as polyacrylamide, and the use thereof in the construction of soluble multivalent macromolecular conjugates
IT1245748B (it) * 1990-12-21 1994-10-14 Mini Ricerca Scient Tecnolog Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego
ZA932523B (en) * 1992-04-10 1994-10-08 Res Dev Foundation Immunotoxins directed against cd33 related surface antigens
ZA932522B (en) * 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
JPH07507804A (ja) * 1992-06-09 1995-08-31 ネオルックス　コーポレーション 予備標的化方法及び化合物
US5482698A (en) * 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
AU683893B2 (en) * 1993-05-17 1997-11-27 Immunomedics Inc. Improved detection and therapy of lesions with biotin/avidin-metal chelating protein conjugates
WO1995015979A1 (en) * 1993-12-07 1995-06-15 Neorx Corporation Pretargeting methods and compounds

Also Published As

Publication number Publication date
JPH09508792A (ja) 1997-09-09
WO1995021195A1 (en) 1995-08-10
NO319899B1 (no) 2005-09-26
NO963283L (no) 1996-08-06
NZ281763A (en) 2001-06-29
AU695564B2 (en) 1998-08-13
EP0743958B1 (en) 2003-07-23
FI963103A (fi) 1996-10-01
CN1200950C (zh) 2005-05-11
ATE245662T1 (de) 2003-08-15
RU2164943C2 (ru) 2001-04-10
KR100376390B1 (ko) 2003-06-12
AU1868795A (en) 1995-08-21
JP4015693B2 (ja) 2007-11-28
EP0743958A4 (en) 1999-07-28
SA95150519B1 (ar) 2005-07-24
EP0743958A1 (en) 1996-11-27
IL112372A0 (en) 1995-03-30
US6214974B1 (en) 2001-04-10
NO963283D0 (no) 1996-08-06
IL112372A (en) 2001-08-26
DE69531342D1 (de) 2003-08-28
KR970700771A (ko) 1997-02-12
CN1143374A (zh) 1997-02-19
CA2182616A1 (en) 1995-08-10

Similar Documents

Publication Publication Date Title
FI963103A (fi) Ei-virusvektori
DK1075282T3 (da) PEG-LHRH-analog-konjugater
ES2194114T3 (es) Formulaciones liposomicas de mitoxantrona.
GB2340121B (en) Delivery system
IL130823A0 (en) Peptide-lipid conjugates liposomes and liposomal drug delivery
GR3034204T3 (en) Lipopolyamines as transfection agents and pharmaceutical uses thereof
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
ZA9810122B (en) Treatment of T-helper cell type 2 mediated immune diseases
AU5658196A (en) Method for pharmaceutical delivery
MX9806041A (es) Proteina purificada sr-p70.
IL118218A0 (en) Terpenoidic derivatives and pharmaceutical compositions containing them
WO1999012945A3 (en) Hydrophobic glycosylamine derivatives, compositions, and methods for use
AU1373197A (en) Covalent lipid-phosphonocarboxylic acid conjugates, the production thereof as well as their use as antiviral pharmaceutical agents
AU5685300A (en) Solid preparations containing paroxetine
ATE211489T1 (de) Chitosan enthaltende zusammensetzung
AU2002218203A1 (en) Transferrin-polycation/dna complexes for the systemic treatment of tumour diseases using cytotoxic proteins
WO1998051792A8 (en) Fac molecules and uses thereof
CA2458872A1 (en) Human ubiquitin-conjugating enzyme
AU4426996A (en) Therapeutic compound - fatty acid conjugates
ZA964925B (en) Pharmaceutical compositions for gene therapy.
SI0898477T1 (en) Topical administration of premafloxacin for the treatment of systemic bacterial diseases
MX9708877A (es) P62, sus variantes, las secuencias de acidos nucleicos que los codifican, y su utilizacion en terapia genica anti-cancerosa.

Legal Events

Date Code Title Description
FD Application lapsed